Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Factors in the Tumor Microenvironment Promote Cancer Growth and Metastasis

By BiotechDaily International staff writers
Posted on 13 Aug 2014
Cancer researchers have found that procancerous HSF1 (Heat shock factor 1) drives a transcriptional program in cancer-associated fibroblasts (CAFs) that complements, yet is completely different from, the program it drives in adjacent cancer cells.

Stromal cells within the tumor microenvironment are essential for tumor progression and metastasis, but little is known about the factors that drive the transcriptional reprogramming of stromal cells within tumors. Investigators at the Whitehead Institute for Biomedical Research (Cambridge, MA, USA) recently reported that the transcriptional regulator heat shock factor 1 (HSF1) was frequently activated in cancer-associated fibroblasts (CAFs), where it was a potent enabler of malignancy. HSF1 activity was found in a variety of human tumors, including breast, lung, skin, esophageal, colon, and prostate cancers.

HSF1 is the major regulator of heat shock protein transcription in eukaryotes. In the absence of cellular stress, HSF1 is inhibited by association with the heat shock proteins Hsp40/Hsp70 and Hsp90 and is therefore not active. Cellular stresses, such as increased temperature, can cause misfolding of proteins in the cell. Heat shock proteins bind to the misfolded proteins and dissociate from HSF1. This allows HSF1 to form trimers and translocate to the cell nucleus where it is hyperphosphorylated, binds to DNA containing heat shock elements, and activates transcription.

The investigators reported in the July 31, 2014, issue of the journal Cell that analysis of tumor samples from breast cancer and non-small-cell lung cancer patients revealed that HSF1 activation in the stroma was associated with poor patient outcomes, including reduced disease-free survival and overall survival. Thus, stromal HSF1 is considered to be a possible biomarker for cancer diagnosis and prognosis as well as a potential drug target.

“This is actually a beautiful example of evolution,” said Dr. Ruth Scherz-Shouval, a postdoctoral researcher at the Whitehead Institute for Biomedical Research. “It is recognizing that the tumor is like an organism that adheres to evolutionary principles. HSF1 has been highly conserved over time, supporting the survival of organisms ranging from yeast to human, so it makes sense that it is coopted here. Both cancer cells and the microenvironment are sensing changes in the tumor and responding, signaling to one another to help the “organism,” albeit to the detriment of the host. These are different programs, but they are both controlled by HSF1 and serve the same purpose.”

“It is important to find HSF1 operating this way in the stroma,” said Dr. Scherz-Shouval. “The tumor microenvironment tends to be more genetically stable and less prone to mutation, suggesting that even if cancer cells could mutate to evade therapeutic disruption of HSF1, supportive cells in the stroma could still be susceptible.”

Related Links:

Whitehead Institute for Biomedical Research



comments powered by Disqus

Channels

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.